|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
02186 LUYE PHARMA
Nominal 
3.810 -0.070 (-1.804%) | 2025/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | |
| Turnover | 3,181,110 | 3.465% | 6,061,441 | 6,143,078 | 5,981,656 | 5,200,226 |
| Cost of Sales | (1,023,501) | 2.758% | (2,017,214) | (1,938,903) | (1,841,140) | (1,803,486) |
| Gross Profit | 2,157,609 | 3.804% | 4,044,227 | 4,204,175 | 4,140,516 | 3,396,740 |
| 2025/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | (12,022) | -- | (774) | 794 | 831 | 701 | |
| Profit / (Loss) before Taxation | 457,640 | -13.649% | 839,219 | 700,100 | 669,762 | (74,557) | |
| Taxation | (100,257) | 9.214% | (194,211) | (161,023) | (86,466) | (70,226) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | (44,497) | -11.611% | (173,122) | (6,472) | 21,511 | 10,391 | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | 312,886 | -19.325% | 471,886 | 532,605 | 604,807 | (134,392) | |
| 2025/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | |
| Net Finance Costs / (Income) | 338,460 | 44.558% | 477,353 | 558,317 | 383,082 | 297,462 |
| Depreciation & Amortisation | 408,138 | 17.178% | 790,672 | 701,851 | 671,313 | 581,982 |
| Directors' Emoluments | -- | -- | 8,784 | 11,788 | 10,218 | 10,694 |
| 2025/06 - Interim | %Chg (Compare to Interim) | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| Auditor's Opinion Status | N/A | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2025/06 - Interim | %Chg (Compare to Interim) | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| EPS (cts) | 8.320 | -19.302% | 12.540 | 14.290 | 17.380 | -3.900 |
| DPS (cts) | 0.000 | -- | 0.000 | 0.000 | 0.000 | 0.000 |
| Dividend Payout Ratio (%) | -- | -- | -- | -- | -- | -- |
| Cash flow per share ($) | -- | -- | 0.045 | 0.428 | 0.475 | 0.053 |
| NBV per share ($) | 3.906 | -- | 3.640 | 3.229 | 2.867 | 2.314 |
| Remarks: | Real time quote last updated: 09/09/2025 17:59 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB 312,886 |
| %Change | -19.325% |
| EPS / (LPS) | RMB 0.083 |
| NBV Per Share (¥) | RMB 3.906 |